Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Andtbacka

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancer Biology & Therapy|May 24, 2005
Velcade displays promising activity in primary effusion lymphoma cellsDavid McConkey, Steffan T Nawrocki, Robert Andtbacka
Molecular Cancer Therapeutics|September 21, 2006
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cellsSanaz Khanbolooki, Steffan T Nawrocki, Thiruvengadam Arumugam, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2009
MelanomaDaniel G Coit, Robert Andtbacka, Christopher K Bichakjian, et al.
Annals of Surgical Oncology|February 23, 2017
The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous MelanomaMaris S Jones, Peter C Jones, Stacey L Stern, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 7, 2012
MelanomaDaniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
Melanoma, version 2.2013: featured updates to the NCCN guidelinesDaniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
Melanoma, version 4.2014Daniel G Coit, John A Thompson, Robert Andtbacka, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
NCCN Guidelines Insights: Melanoma, Version 3.2016Daniel G Coit, John A Thompson, Alain Algazi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Alain Algazi, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer Biology & Therapy|May 24, 2005
Velcade displays promising activity in primary effusion lymphoma cellsDavid McConkey, Steffan T Nawrocki, Robert Andtbacka
Molecular Cancer Therapeutics|September 21, 2006
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cellsSanaz Khanbolooki, Steffan T Nawrocki, Thiruvengadam Arumugam, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2009
MelanomaDaniel G Coit, Robert Andtbacka, Christopher K Bichakjian, et al.
Annals of Surgical Oncology|February 23, 2017
The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous MelanomaMaris S Jones, Peter C Jones, Stacey L Stern, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 7, 2012
MelanomaDaniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
Melanoma, version 2.2013: featured updates to the NCCN guidelinesDaniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
Melanoma, version 4.2014Daniel G Coit, John A Thompson, Robert Andtbacka, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
NCCN Guidelines Insights: Melanoma, Version 3.2016Daniel G Coit, John A Thompson, Alain Algazi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Alain Algazi, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Pageof 1